Vertex Pharmaceuticals (VRTX)

In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed the release of highly encouraging clinical data and operational updates from its renal pipeline, specifically targeting

Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 8.3% in the afternoon session after the company announced positive resul...

The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry darlings. As of March 10, 2026, the industry is processing a tale of two trajectories: Vertex Pharmaceuticals (NASDAQ: VRTX) has cemented

Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER trial. The data, which focused on povetacicept for the treatment of IgA nephropathy (IgAN), showcased a 52% reduction in proteinuria, a

Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing.

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

The company has performed well over the long run.

Both of these players are leaders in their fields.

These two biotechs have a lot in common. Their differences are even more pronounced.

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Patience should pay off with these two healthcare giants.

One of these is not like the other.

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total transaction value of up to $2.4 billion. The deal centers on Orna’s proprietary circular RNA (oRNA)

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.

This biotech powerhouse could maintain its strength for the long term.

Even a great stock has a ceiling.

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.